Dyne Therapeutics Hits Milestone with Promising Duchenne Drug, Eyes 2026 Approval

Dyne Therapeutics' experimental DMD treatment shows strong results in late-stage trial, potentially offering more effective alternative to current controversial therapies with 10x higher dystrophin levels.